Background: The addition of arachidonic acid (AA) and docosahexaenoic acid (DHA) to infant formula was recently approved in North America. In piglets, dietary AA is linked to elevations in bone mass. Objective: The objective was to investigate the effects of varied amounts of dietary AA on bone modeling and bone mass with the use of the piglet model for infant nutrition. Design: Male piglets (n ϭ 32) were randomly assigned to receive 1 of 4 formulas supplemented with AA (0.30%, 0.45%, 0.60%, or 0.75% of fat) plus DHA (0.1% of fat) from days 5 to 20 of life. Measurements included biomarkers of bone modeling, fatty acid status, and whole-body and femur bone mineral content; bone area was measured by dual-energy X-ray absorptiometry. Differences among groups were detected with two-factor analysis of variance. Regression analyses were used to determine factors responsible for bone mineral content after dietary AA was accounted for. Results: Proportions of AA in plasma, liver, and adipose were modified by the dietary treatments, but bone modeling was not affected. Liver AA was positively related to plasma insulin-like growth factor 1 and calcitriol and urinary N-telopeptide. Wholebody bone mineral content was elevated in the piglets fed 0.60% and 0.75% AA and was best predicted by dietary AA and bone resorption. Conclusions: This study confirms that dietary AA alters bone mass and clarifies the best amount of AA to add to the diet of pigs born at term. Because the amount of dietary DHA was held constant, whether other amounts of DHA are related to bone mass requires investigation.
INTRODUCTION
Infant formula products are designed to mimic the qualities of human milk and are formulated based on the most current state of science. The quality of fat in infant formula was recently revised in North America. For decades, infant formulas have contained the essential nϪ6 and nϪ3 polyunsaturated fatty acids (PUFAs) linoleic acid (18:2nϪ6) and linolenic acid (18:3nϪ3) in a ratio of Ϸ9:1. Some commercially available formulas now contain the long-chain PUFAs arachidonic acid (AA, 20:4nϪ6) and docosahexaenoic acid (DHA, 22:6nϪ3). Similac Advance (AA:DHA ϭ 0.4%:0.15%, a 2.7:1 ratio; Ross Products Division of Abbott Laboratories, Columbus, OH) and Enfamil Lipil (AA:DHA ϭ 0.64%:0.32%, a 2:1 ratio; Mead Johnson Nutritionals, Evansville, IN) are sold in the United States, and Enfalac A ϩ (AA:DHA ϭ 0.64%:0.32%, a 2:1 ratio; Mead Johnson Nutritionals) is sold in Canada. The evidence supporting these ratios is based on decades of research regarding safety and on the relation between infant fatty acid status and visual and cognitive development (1) (2) (3) (4) .
The ratio of dietary nϪ6 to nϪ3 PUFAs is becoming recognized as also playing a role in bone biology (5) (6) (7) . Candidate PUFAs with the potential to enhance bone mass include ␥-linolenic acid (GLA, 18:3nϪ6), AA, eicosapentaenoic acid (EPA, 20:5nϪ3), and DHA. In young rats, a dietary total nϪ6:nϪ3 ratio of 3:1 combined with GLA and EPA in 4.1:1 ratios enhance bone calcium and calcium balance after 42 d (8) . A lower ratio of GLA to EPA of 1.8:1 and a total nϪ6:nϪ3 ratio of 1:1 only moderately elevates femur bone calcium (8) . In rats of similar ages, a reduction in the total nϪ6:nϪ3 dietary ratio of from 23.8:1 to 2.6:1 or to 1.2:1 by the addition of fish oil elevates total alkaline phosphatase over 42 d, but does not affect the bone formation rate (9) . In our laboratory, the addition of AA and DHA to formula in ratios of Ϸ5:1 (0.5:0.1% of dietary fat) elevates bone mass over 14-15 d in piglets when the total nϪ6:nϪ3 ratio is 5:1 (10) or 9:1 (11) .
On the basis of the studies highlighted above, the optimal amount and type of PUFA required to enhance bone mass is not clear. Claassen et al (8) and Watkins et al (9) not only modified diets by adding GLA, EPA, or both but also modified the total 18:2nϪ6 and 18:3nϪ3 contents of the diet. This resulted in confusion as to whether it is the total nϪ6:nϪ3 ratio or the specific PUFA that affects bone. Previously, we added AA and DHA while keeping the total nϪ6:nϪ3 ratio relatively stable (10, 11) , which suggests that AA, DHA, or both were responsible for the elevated bone mass and not the total nϪ6:nϪ3 ratio. It is notable that the studies that report higher bone mineral mass used both nϪ6 and nϪ3 PUFA supplementation; Claassen et al (8) used GLA:EPA in a 4:1 ratio and Weiler (10) used AA:DHA in a ratio of Ϸ5:1. By design, the status of EPA and DHA was unchanged in our previous study, but the status of AA was elevated (10) . However, it is not clear how much AA is required to optimize the development of bone mass. Because AA and DHA are now added to some infant formulas, it is important to investigate their potential to affect bone during early life. Therefore, this study was designed to investigate the effects of varied amounts of dietary AA, while keeping the DHA status and the total nϪ6:nϪ3 PUFA constant, on bone modeling and bone mass. Whether varying the amount of DHA affects bone will be investigated separately. The piglet model was selected for continued study to enable comparison with our previous studies (10, 11) .
MATERIALS AND METHODS
The experimental design used was a 15-d researcher-blind, randomized block design. Male piglets (3 d old) were obtained from Glenlea Research Station, University of Manitoba. All piglets were randomly assigned within litters to 1 of 5 groups on day 3 of life so that only 1 piglet per litter represented each group. Eight of the piglets remained with the sows and were sow-reared for the remainder of the study. Thirty-two piglets were removed from the sows and transported to the University of Manitoba Animal Care Facility. Piglets in the formula groups were to receive 1 of 4 cow milk-based formulas for 15 d. The formulas provided optimal nutrition for healthy growing piglets as set by the National Research Council (12) . Group 1 received AA:DHA at a 3.0:1.0 ratio (0.3:0.1% wt/wt of total dietary fat), group 2 received AA:DHA at a 4.5:1.0 ratio (0.45:0.1% wt/wt of total dietary fat), group 3 received AA:DHA at a 6.0:1.0 ratio (0.6:0.1% wt/wt of total dietary fat), and group 4 received AA:DHA at a 7.5:1.0 ratio (0.75:0.1% wt/wt of total dietary fat). Ratios of AA to DHA referred to in dietary treatment groups are the target ratios. The formulas used in the study were provided by Ross Products Division of Abbott Laboratories (product no. P96-AV2). The composition of the base formula is presented in Table 1 . AA was provided in the form of RBD-ARASCO (40.6% AA) and DHA as RBD-DHASCO (40.0% DHA). DHA is derived from a marine microalgae (DHASCO), and AA is derived from a common soil fungi (ARASCO); both were provided by Martek Biosciences Corp (Columbia, MD) and selected as the source because these products are also used in the manufacture of human infant formula. Group 5 was a sow-reared reference group. For comparison, the milk from the sows in this study contained 0.54% of the fat as AA and 0.07% as DHA and had a total nϪ6:nϪ3 fatty acid ratio of 6.9:1.0.
Formula-fed piglets were housed individually in stainless steel cages under heat lamps to maintain an ambient temperature of 28-30°C. On day 3 of life, the piglets were taught to lap liquid formula and were fed standard formula at half strength. By the end of day 4 of life, the formula strength was increased to three-fourths the full strength. Before each morning feeding, the piglets in each of the 4 formula treatment groups were weighed by digital scale (Mettler-Toledo Inc, Highstown, NJ) with an animal-weighing program (average of 3 weights). Those in the sow-reared group were weighed at 0900 daily, which represents a fed state.
On the basis of morning weights, the formula-fed groups received formula at 350 mL · kg Ϫ1 · d Ϫ1 . This amount was divided into 3 equal amounts and fed to piglets at 0900, 1500, and 2100. Piglets were allowed Ϸ1 h of exercise in a pen outside their cages before each feeding. Piglets in group 5 (sow-reared) were maintained according to standard housing conditions at the research station. The pigs were exposed to 16 h of light and 8 h of darkness and were penned with the sow, allowing some room for physical activity. Piglets within a litter and not part of the study were allowed to be cross-fostered to the sows in this study, but a maximum of 10 piglets per sow was maintained throughout the study.
The experimental procedures were approved by the Fort Garry Campus Protocol Management and Review Committee, University of Manitoba, and were in agreement with the Guide to the Care and Use of Experimental Animals (13) . The growth rate of all piglets was determined by calculating an average daily weight gain as follows:
Weight gain ϭ [change of weight in g/(weight in kg on day 1 ϩ weight in kg on day 15 
Sow-fed piglets were transferred from the Glenlea Research Station to the University of Manitoba on the evening of the 15th day of treatment. All piglets were fed only water ad libitum after 1800, which resulted in 14 h in the nonfed state. On the morning of the 16th day, piglets were anesthetized with an intraperitoneal injection of 30 mg sodium pentobarbital/kg (65 mg/mL). The animal's length was then measured with a nonstretchable measuring tape from the tip of the snout to the base of the tail (to the nearest 0.1 cm). Once deep anesthesia was achieved, a cardiac puncture was performed and Ϸ50 mL blood was drawn into heparin-containing syringes. Samples were centrifuged at 2000 ϫ g and 4°C for 15 min (model TJ-6R tabletop centrifuge; Beckman, Palo-Alto, CA) to separate red blood cells from plasma and were then flushed with liquid nitrogen and stored at Ϫ80°C until analyzed for fatty acid composition and biomarkers in plasma. After the removal of blood, the animals were terminated with a sodium pentobarbital overdose (180 mg/kg). Liver and tibia (Ϸ1.0 g) samples were excised, rinsed with 0.9% NaCl, and weighed to the nearest 0.1 g. Liver tissue was flash frozen in liquid nitrogen and stored at Ϫ80°C. Urine was collected in a syringe via bladder puncture and stored at Ϫ20°C.
Total lipids in plasma and tissues were extracted with the use of methanol:chloroform (1:2, by vol) according to the method of Folch et al (14) as previously described (10, 11 ). An internal standard, heptadecanoic acid (17:0), was added to each sample. Crude lipid extracts were transmethylated in 1 mL methanolic HCl (3N; Supleco Inc, Bellefonte, PA) at 100°C for 15 min. Brain was extracted and methylated by using the same method but was methylated over 90 min. Fatty acid methyl esters were separated by gas-liquid chromatography (Varian Star 3400; Varian, Mississauga, Canada) with the use of hydrogen as the carrier gas. The gas chromatograph was equipped with a 30-m long capillary column made of fused silica and coated with DB225 (25% cyanopropylphenyl; J&W Scientific, Folsom, CA), an 8100 autosampler, an integrator, and a flame ionization detector. Samples were injected (0.5 L) at an initial temperature of 180°C, and then the oven temperature was increased to a final temperature of 220°C at a rate of 3°C/min. Fatty acid methyl esters (carbon chain lengths of 10-24) were identified by comparison with retention times of Supelco 37 component FAME mix (Supelco Inc) and expressed as a percentage of total fatty acids.
Plasma osteocalcin was analyzed by using a radioimmunoassay (DiaSorin, Stillwater, MN). Urinary N-telopeptide (NTX) was measured in urine by using an enzyme-linked immunosorbent assay (Osteomark; Ostex, Seattle). NTX was corrected to creatinine as measured by using the Jaffe method (procedure no. 555; Sigma-Aldrich Ltd, Oakville, Canada). The concentration of intact parathyroid hormone (PTH) was determined in plasma by using an immunoradiometric assay (DiaSorin), and calcitriol concentrations were measured in plasma by using a radioimmunoassay (Diasorin). Total transforming growth factor ␤-1 (TGF␤-1) was assayed in plasma by using an enzyme-linked immunosorbent assay (R & D Systems, Minneapolis, MN) as used in recent cell culture experiments (15, 16) . Plasma concentrations of insulin-like growth factor I (IGF-I) were measured with an enzyme-linked immunosorbent assay (R & D Systems).
The ex vivo release of prostaglandin E 2 (PGE 2 ) and TGF␤-1 was measured in an approximately 1-g segment of tibia incubated in Hank's Balanced Salt Solution for 2 h at 37°C, according to the method of Dekel et al (17) . This method was selected because it has been used in chicks (18) , rats (9) , and piglets (19) to assess prostanoid metabolism after dietary treatment. Briefly, bone was sampled from the mid-diaphysis to represent cortical bone after removal of periosteum and marrow. The released PGE 2 was analyzed in diluted samples by using an enzyme-linked immunosorbent assay (R&D Systems) and corrected to the weight of the tibia segment studied. Total TGF␤-1 was measured by using the same enzyme-linked immunosorbent assay kit that was used for plasma but was expressed per unit of tibia segment studied. This method provides for total TGF␤-1 and not TGF␤-1 activity, which requires bioassays (20) . Release of TGF␤-1 by using a similar approach was conducted in tissue culture, in which osteoid matrix breakdown was measured 2 h after the addition of osteoclasts (20) . Whether 2 h is the optimal duration of incubation for both PGE 2 and TGF␤-1 requires clarification in subsequent experiments.
After the tissues were removed, the abdominal cavity was closed with sutures to maintain tissue depth. Piglet carcasses were then transported to a dual-energy X-ray absorptiometer (QDR4500W; Hologic Inc, Waltham, MA). Single scans were completed to determine the bone mineral content (BMC) and areas of the whole body (software version V8.16a:5) and left femur with the use of the subregion array hip program. All scans were performed with the piglets in the anterior-posterior position with limbs extended.
Statistical analysis
Values are expressed as means Ϯ 1 SD unless stated otherwise. Statistical significance was set at a P value Յ 0.05. The sample size, n ϭ 8 per group, was calculated on the basis of a change of 25 Ϯ 13 g in whole-body BMC as reported in the same species of animal (10) fed a formula with an AA:DHA ratio (5.0:1.0) similar to that in the present study. The power was set at 0.80 and ␣ ϭ 0.05. Differences in outcome measurements were detected by using a two-factor (litter and dietary treatment) analysis of variance for a randomized block design and post hoc analyses with the Bonferroni post hoc test to indicate differences among the formula-fed groups. Interactions among the litters and diets were not tested, because only one piglet per litter represented each diet. Pearson's correlation analyses were used to identify factors measured in tissues or the circulation (AA in liver and plasma IGF-I, TBF␤-1, PTH, calcitriol, NTX, and osteocalcin) or localized to bone (PGE 2 and TGF␤-1) that were related to the dietary treatment and bone mass. To determine which variables, after diet was accounted for, contributed to the prediction of bone mass, the same factors used in the correlation analyses with significant linkages to diet or bone were entered into backward stepwise regression. The sow-reared group was not compared with the use of statistical tests but was used as a target reference group for outcome measurements.
RESULTS
The growth of piglets was measured daily to determine whether differences existed between treatment groups. The average weights of the piglets were not significantly different between the formula-fed groups at baseline or after 15 d of treatment. No significant differences in weight gain occurred between formula-fed groups throughout the study. Length was also not significantly different between the formula groups at the end of study. The size and growth rate of the piglets in the sow-reared reference group paralleled that of the formula-fed groups ( Table 2) . No significant differences in formula intakes were observed between the treatment groups (sow-reared group intake was not measurable).
After 15 d of dietary treatment, plasma, liver, adipose, and brain fatty acids were analyzed. No significant differences in the saturated and monounsaturated fatty acid content of all tissues were found between formula groups (data not shown). After correction for the effects of litter, supplemental AA in the formula was reflected in plasma, liver, and adipose tissues but not in brain (Tables 3-5) . Elevated AA did not alter the proportion of other nϪ6 and nϪ3 fatty acids, except for brain DHA, which was lower in the 4.5:1 formula group than in the other 3 groups (Table  5) . A main effect of litter was observed for 18:2nϪ6 and DHA in plasma, 18:2nϪ6 and AA in liver, and AA and DHA in brain. No effects of litter were observed for adipose. were not detected in adipose or brain in amounts Ͼ0.05% of total fatty acids. The sow-reared reference group represented the same 8 litters; n ϭ 1 per litter, n ϭ 8 total. AA, arachidonic acid; DHA, docosahexaenoic acid. Values in a row with different superscript letters are significantly different, P Ͻ 0.05.
2 Ratios represent the percentage of fatty acids in the formula. 3 Post hoc testing was conducted only to determine differences between formula groups. 4 x Ϯ SD. 5 Post hoc testing indicated that formula groups were not significantly different.
Results of the two-factor analysis of variance indicated that after 15 d of treatment, the AA:DHA ratio of the formula had a significant main effect on whole-body BMC (P ϭ 0.038). A significant effect of litter was not observed. Post hoc analysis indicated that groups 3 and 4 had higher values than did groups 1 and 2 (P Ͻ 0.05) (Figure 1) . Whole-body bone area followed the same pattern as did BMC, but the main effects of litter (P ϭ 0.318) and diet (P ϭ 0.055) were not significant (Figure 1 ). Femur BMC was not significantly different between groups: 2.0 Ϯ 0.4 g for group 1, 2.2 Ϯ 0.7 g for group 2, 2.2 Ϯ 0.4 g for group 3, 2.4 Ϯ 0.2 g for group 4, and 3.7 Ϯ 0.8 g for the sow-reared group. Femur bone area was affected significantly by litter (P ϭ 0.018) but not by dietary treatment (P ϭ 0.351); mean values were 8.4 Ϯ 1.5 cm 2 for group 1, 8.2 Ϯ 1.6 cm 2 for group 2, 8.6 Ϯ 1.2 cm 2 for group 3, and 9.1 Ϯ 0.6 cm 2 for group 4. The value for bone area in the sow-reared group was 11.0 Ϯ 1.6 cm 2 . Although statistical comparisons were not made to determine significance, for all measurements of BMC the sow-reared group had higher values on average than did the formula-fed groups, regardless of formula group.
Modeling and resorption of collagen matrix was assessed by analyzing NTX in urine samples. The results were then normalized for urine dilution by dividing values by urinary creatinine; no significant differences were found between groups ( Table 6 ). Plasma osteocalcin was analyzed to assess osteoblast activity. No significant differences were observed between groups (Table 6 ). Differences in plasma PTH, IGF-I, calcitriol, and TGF␤-1 and in urinary cortisol were not observed between the formula-fed groups. Release of TGF␤-1 and PGE 2 from bone was not significantly different among formula groups and litters ( Table 6 ). Effects of litter were observed for plasma PTH and urinary NTX.
Dietary AA correlated with AA in plasma (r ϭ 0.44, P ϭ 0.01) but not with liver AA (r ϭ 0.35, P ϭ 0.055) or the variables related to bone metabolism (data not shown). The proportion of AA in plasma and liver did, however, correlate with plasma IGF-I (plasma: r ϭ 0.50, P ϭ 0.004; liver: r ϭ 0.56, P Ͻ 0.001), calcitriol (plasma: r ϭ 0.48, P ϭ 0.006; liver: r ϭ 0.37, P ϭ 0.035), and urinary NTX (liver: r ϭ 0.533, P ϭ 0.002).
Pearson's correlation analysis was conducted to determine any relations between the biochemical variables and bone mass. Whole-body BMC was related to bone TGF␤-1, NTX, and PGE 2 : PTH (r ϭ Ϫ0.12, P ϭ 0.55), bone TGF␤-1 (r ϭ 0.40, P ϭ 0.04), IGF-I (r ϭ 0.28, P ϭ 0.12), plasma TGF␤-1 (r ϭ 0.08, P ϭ 0.07), calcitriol (r ϭ 0.04, P ϭ 0.81), NTX (r ϭ 0.44, P ϭ 0.01), osteocalcin (r ϭ Ϫ0.09, P ϭ 0.06), and PGE 2 (r ϭ 0.38, P ϭ 0.03). Backward stepwise regression was conducted to examine which variables in combination with dietary treatment were most likely responsible for the higher BMC with increasing AA. The only variables that contributed to BMC were dietary AA (P ϭ 0.018) and urinary NTX (P ϭ 0.033), in the regression equation y ϭ 38.01 ϩ 1.82 (dietary AA as % of fat) ϩ 0.90 (NTX as nmol:mmol creatinine), R 2 ϭ 0.607, P ϭ 0.008.
Whole-body bone area was correlated with bone TGF␤-1, NTX, and PGE 2 but not with plasma PTH, IGF-I, TGF␤-1, calcitriol, or osteocalcin: bone TGF␤-1 (r ϭ 0.40, P ϭ 0.04), NTX (r ϭ 0.32, P ϭ 0.07), and PGE 2 (r ϭ 0.48, P ϭ 0.006); plasma PTH (r ϭ Ϫ0.05, P ϭ 0.81), IGF-I (r ϭ Ϫ0.05, P ϭ 0.81), TGF␤-1 (r ϭ 0.04, P ϭ 0.85), calcitriol (r ϭ 0.05, P ϭ 0.78), and osteocalcin (r ϭ Ϫ0.03, P ϭ 0.89). The only variable that contributed significantly to bone area after dietary AA was accounted for (P ϭ 0.004) was urinary NTX (P ϭ 0.034), in the regression line y ϭ 79.04 ϩ 4.49 (dietary AA as % of fat) ϩ 1.74 (NTX as nmol:mmol creatinine), R 2 ϭ 0.66, P ϭ 0.002.
DISCUSSION
The main objective of this research was to examine the effect of varied amounts of AA added to cow milk-based formula on biomarkers of bone modeling and bone mass in the piglet model for infant nutrition. After as little as 15 d, proportions of AA in tissues (plasma, liver, and adipose) were elevated in proportion to diet and, by design, DHA was unaltered. These observations were accompanied by elevations in BMC when AA was Ͼ0.5% of dietary fat, which confirmed the results of previous studies (10, 11) . Whether elevations in bone mass continue after 15 d remains to be determined. This is an important consideration because fatty acid status does not plateau in piglets fed vegetable oil-based formula for Յ25 d (21) . However, our values for AA and DHA were almost identical to those in liver after 29 d (22) and in plasma after 16 d (23) in piglets fed the same dietary sources and similar amounts of AA and DHA. Additionally, after piglets are fed fish oil for 12 d, incorporation of EPA into platelets reaches a steady state plateau (24) . Thus, it is possible that the PUFA status plateaus quicker when dietary AA and DHA are provided in comparison with diets devoid of these fatty acids (21) . This theory is supported by an insignificant change in serum AA in human infants after 2-6 wk of consuming formula made with AA and DHA in contrast with significant reductions after 2 wk in infants fed unsupplemented formula (25, 26) .
The mechanisms behind the elevations in bone mass with Ͼ0.5% AA are probably linked to the resorption and modeling of bone. Whole-body BMC was correlated with NTX, bone TGF␤-1, and bone PGE 2 but not with the circulating growth factors or hormones (PTH, calcitriol, IGF-I, and TGF␤-1). In rats, TGF␤-1 is linked to the stimulation of bone formation (27) and healing (28) . However, AA status was not related to bone TGF␤-1 or PGE 2 but was related to IGF-I, calcitriol, and NTX in the piglets. Regression analyses indicated that after the dietary groups were accounted for, whole-body BMC was best predicted by NTX. This was the case for bone area as well, which suggests that a higher turnover was associated with modeling of bone and not with loss of mineral. The observation that both BMC and bone area were elevated supports this interpretation. This observation agrees with that by Claassen et al (8) , in which a ratio of GLA to EPA of 1.8:1 resulted in lower values for bone resorption and lower bone calcium than did a ratio of 4.1, although the total nϪ6:nϪ3 ratios varied as well.
It is important to note that NTX values in the piglets were within the expected range (10, 11) and were not elevated by the dietary treatments directly. AA status was modified by diet and was related to NTX as well as to IGF-I and calcitriol but not to TGF␤-1 or PGE 2 . In chicks, EPA and DHA (fish oil) elevate IGF-I (18), but this was not the case in piglets fed AA and DHA. Thus, whereas calcitriol, IGF-I, TGF␤-1, and PGE 2 are all linked to bone modeling (7, 27) , the role of each in modulating bone modeling and mass as a result of feeding dietary AA is unclear.
There are no reports of bone mass in infants fed formula with AA and DHA and, thus, the results of this study should not be extrapolated to human infants. In the piglets, liver AA was positively related to urinary NTX, which suggests that lower amounts of AA are linked to lower bone modeling and resorption. Infants who are born prematurely have elevated rates of bone resorption and delayed bone growth (29) (30) (31) . Whether dietary AA would benefit bone growth in preterm infants is unknown. Interestingly, high rates of bone turnover continue up to 8-12 y of age in children who were born preterm (32) and also in males aged 19-21 y who were born of low birth weight (33) . In addition, growth in the first year of life is known to relate to adult bone mass (34) (35) (36) . These studies suggest that bone mass and metabolism are programmed by events in early life. Whether dietary AA can program bone modeling or pre- vent the long-term sequelae of low bone mass and high turnover osteopenia due to prematurity or size at birth is not known. Longer-term supplementation studies are needed in which AA is supplemented early in life and in which bone mass is assessed at maturity in humans and other mammals. A suckled piglet group was included as a target reference group because the objective of designing infant formula is to mimic the qualities of mothers' milk. Although the BMC of the reference group was higher, the piglets fed the higher amounts of AA (0.6-0.75%) had BMC values closest to that of the reference group. The weight and length of the piglets were not affected by feeding mode (suckling compared with formula), which indicated that the growth rate was not a confounding variable. The higher BMC in the suckled piglets may have been linked to environment and other nutritional qualities of maternal milk other than those from PUFAs. The suckled piglets would be exposed to shorter more frequent bouts of weightbearing activity than would the formula-fed groups, for which exercise was permitted 3 times daily. In rats, shorter more frequent loading sessions lead to higher bone masses than does the same amount of loading delivered over one session daily (37) . In human infants the environment is more similar between infants who are breastfed or fed infant formula. Yet a positive effect of duration of feeding mothers' milk on bone mass has been observed in prepubertal children who were born preterm (38) or term (39) . It is postulated that greater nutrient bioavailability of minerals in maternal milk (40) and physiologic responses such as elevated circulating IGF-I (41) and osteocalcin (42) may be linked to enhanced bone mass in human neonates fed mothers' milk. Both IGF-I and osteocalcin in human neonates are measured in the fed state. The lack of effect of AA and DHA on IGF-I and osteocalcin in the piglets might have been due to measurement in the nonfed state.
As part of a global objective of research designed to establish whether dietary AA enhances bone mass during growth, our research group is interested in other effects in vulnerable or rapidly growing tissues such as the brain. Brain fatty acids were determined to ensure that the amounts of AA and DHA were supportive of expected tissue amounts of AA and DHA in comparison with sow-reared piglets. Values for brain AA and DHA were not significantly different between formula groups fed AA:DHA at a ratio of 6.0:1 or 7.5:1 and were within the range of the sow-reared group. This suggests that the addition of AA to formula can enhance bone without compromising DHA in the brain if DHA is provided as Ն0.1% of dietary fatty acids. Additionally, AA stored in adipose may provide a source of AA when needs exceed intake.
In summary, although it is unclear whether continued dietary supplementation with AA will result in sustained elevations in bone mass, it is clear that short-term supplementation with AA elevates BMC in piglets. It was shown previously that 0.5% of AA as dietary fat has positive effects on BMC when the content of DHA is kept constant at 0.1% of total fat and the total nϪ6:nϪ3 ratio is Ͻ9:1 (10, 11) . Given the narrow range of AA used in the current study (0.30-0.75% of dietary fat), the findings are significant and important for clarifying the optimal amount of AA to be added to infant formula products. Whether the amount of DHA interacts with AA to affect bone remains unclear because our studies to date have only evaluated supplementation with DHA at 0.1% of dietary fatty acids. Further studies in which AA is held constant at 0.5-0.6% of dietary fat but in which DHA is added in amounts ranging from 0.1% to 0.3% of dietary fatty acids are needed to ensure that the role of both nϪ6 and nϪ3 fatty acids early in development are elucidated. Interestingly, some commercial infant formula products (Mead Johnson Nutritionals) contain 0.64% of dietary fat as AA and 0.32% as DHA. Whether there is benefit to human infant bone mass of such a formula has not been reported. Nonetheless, although the design of milk formula substitutes to mimic the qualities of human milk is important and because mothers' milk is associated with enhanced bone mass in humans and pigs, strategies to prolong the duration of breastfeeding continue to be in the best interest of whole-body infant development.
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